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Abstract
Background: Hyponatremia secondary to the syndrome of inappropriate secretion of antidiuretic
hormone is an uncommon complication of treatment with the new class of antidepressant agents,
the selective serotonin reuptake inhibitors. The risk of hyponatremia seems to be highest during
the first weeks of treatment particularly, in elderly females and in patients with a lower body
weight.
Case Presentation: A 61-year-old diabetic male was admitted to the hospital because of malaise,
progressive confusion, and a tonic/clonic seizure two weeks after starting citalopram, 20 mg/day.
On physical examination the patient was euvolemic and had no evidence of malignancy, cardiac,
renal, hepatic, adrenal or thyroid disease. Laboratory tests results revealed hyponatremia, serum
hypoosmolality, urine hyperosmolarity, and an elevated urine sodium concentration, leading to the
diagnosis of inappropriate secretion of antidiuretic hormone. Citalopram was discontinued and
fluid restriction was instituted. The patient was discharged after serum sodium increased from 124
mmol/L to 134 mmol/L. Two weeks after discharge the patient denied any new seizures, confusion
or malaise. At that time his serum sodium was 135 mmol/L.
Conclusions: Because the use of serotonin reuptake inhibitors is becoming more popular among
elderly depressed patients the present paper and other reported cases emphasize the need of
greater awareness of the development of this serious complication and suggest that sodium serum
levels should be monitored closely in elderly patients during treatment with citalopram.
Background
Hyponatremia secondary to the syndrome of inappropri-
ate secretion of antidiuretic hormone (SIADH) is an
uncommon complication of treatment with the new class
of antidepressant agents, the selective serotonin reuptake
inhibitors (SSRIs) [1,2]. Estimations of the occurrence of
hyponatremia during treatment with SSRIs range between
0.5% and 25%, and the risk of hyponatremia seems to be
greatest during the first weeks of treatment with SSRI, in
the elderly, in female patients and in patients with lower
body weights [3,4]. However, severe consequences of
hyponatremia caused SSRIs, such as tonic/clonic seizure,
have not been reported. We describe the case of a 61-year-
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old male with tonic/clonic seizure caused by SSRI-
induced hyponatremia
Case Presentation
We recently saw a 61-year-old male referred to us because
of a 3-day history of malaise, progressive confusion, and a
tonic/clonic seizure. Two weeks before, he had been
started on a regimen of citalopram 20 mg at bedtime. The
patient and his wife reported that he became progressively
confused, lethargic and had difficulty performing simple
tasks. He is a type 2 diabetic treated with metformin 500
mg twice daily and glyburide 2.5 mg once daily. Upon
admission, the patient was afebrile with normal vital
signs. He appeared euvolemic without evidence of conges-
tion or dehydration. Neurologic examination was normal
except for decreased strength on lower extremities. Signif-
icant laboratory findings included sodium of 124 mmol/
L (136–145 mmol/L), potassium of 4.3 mmol/L (3.5–4.5
mmol/L), chloride 86 mg/dL (98–106 mmol/L), blood
urea nitrogen of 3.2 mmol/L (3.6–7.1 mmol/L), creati-
nine 79.56 µmol/L (< 133 µmol/L), glucose of 10.49
mmol/L (4.2–6.4 mmol/L), a uric acid of 150 µmol/L
(150–480 µmol/L) and a serum osmolarity of 263 mosm/
L (285–295 mOsm/L). Urine sodium and urine osmolar-
ity were elevated, 141 mEq/L, and 400 mosm/L, respec-
tively. A CT of the head and an EEG were both normal. An
AM cortisol level, thyroid-stimulating hormone (TSH)
and free thyroxine levels were within normal limits.
Results of a urine toxicology screen revealed no presence
of ethanol or recreational drugs. A citalopram pill count
confirmed compliance with the drug regimen without evi-
dence of overdose.
A diagnosis of SIADH was made based on clinical euvo-
lemia in the presence of hyponatremia with a urine osmo-
larity and sodium that were inappropriately high. Normal
renal, thyroid and adrenal function with relative hipouri-
cemia, all supported SIADH. Extensive investigations
ruled out malignancy, pulmonary, hepatic cardiac or renal
disease or any other known causes of SIADH.
On the day of admission, citalopram was discontinued
and the patient was treated with 2 liters of intravenous
0.9% sodium chloride, phenytoin (5 mg/kg), and subcu-
taneous insulin. Approximately 24 hours after admission
the patient's serum sodium increased to 129 mmol/L
(136–145 mmol/L) and the chloride increased to 89
mmol/L (98–106 mmol/L), thereafter, fluids were
restricted to 1200 ml/day. His mental status improved
over the next 48 hours. Five days after admission serum
sodium was 134 mEq/L (136–145 mmol/L) and serum
chloride was 99 mmmol/L (98–106 mmol/L). Patient was
fully alert, had no more seizures and was subsequently
discharged. At this time phenytoin treatment was stopped.
A follow up serum sodium three weeks after discharge was
135 mmol/L (136–146 mmol/L).
This patient's seizures appear to have been induced by
hyponatremia that was secondary to SIADH, a diagnosis
that is supported by the low serum sodium concentration,
concentrated urine, and clinical evidence of euvolemia.
The laboratory values and history were inconsistent with
a diagnosis of psychogenic polydipsia. The finding of
SIADH secondary to citalopram use may reflect dysregula-
tion of serotonergic control of ADH release or metabo-
lism. Experimental evidence in rodents has demonstrated
the presence of serotonin's neurons in the hypothalamic
supraoptic nucleus, which is where the ADH prohormone
is synthesized[5]. Other studies suggest that serotonin
may be involved in the regulation of ADH release[6]. The
occurrence in this case of a seizure secondary to SIADH-
associated hyponatremia suggests a possible mechanism
for citalopram-induced convulsions and corroborates pre-
vious reports of citalopram-induced SIADH.
Conclusions
The present case and others previously reported, empha-
size the need for greater awareness of the development of
this serious and potentially fatal complication in associa-
tion with citalopram therapy. Review of the present and
previous cases has shown that the onset of citalopram-
induced hyponatremia or SIADH ranges from 6 to 20 days
after the therapy has been started [7-16]. Potential risk fac-
tors for SIADH due to citalopram included advanced age,
female gender, concomitant use of medications known to
cause SIADH or hyponatremia, and possibly, higher cita-
lopram doses [7,8,17]. Therefore, a high level of suspi-
cion, close and careful monitoring of serum sodium
concentration particularly in elderly patients during the
first month of therapy with citalopram may reduce the
incidence of this serious and likely, not rare, adverse
effect.
Although information is not conclusive, other SSRI's
should also be avoided if treatment with an antidepres-
sant had to be restarted in patients with past medical his-
tory of hyponatremia or SIADH induced by citalopram
[17,18].
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